Challenges in the Uptake of Alzheimer’s Disease Drug “Recanemab”: A Closer Look at the Obstacles and Skepticism
On April 23, nine months have passed since the Alzheimer’s disease drug “Recanemab” (US name: Rekenbi) developed by Eisai and US Biogen was officially approved in the United States, but use widespread use of the drug has encountered unexpected obstacles. The photo shows Lynn Castellano receiving lecanemab treatment at the Medical Center in St. Louis, […]
Eisai to begin administering new Alzheimer’s drug in China, expects significant growth in 2025
/cloudfront-us-east-2.images.arcpublishing.com/reuters/6JNAGOI2C5MTNMYJUKLOR6I6QY.jpg?fit=1024%2C1024&ssl=1)
On February 4, the major pharmaceutical company Eisai aims to start giving lecanemab, a new Alzheimer’s disease drug developed jointly with the US company Biogen, to 1,500 people in China by the end of the year. In this photo, a scientist looks at a brain scan at a university hospital in Geneva, Switzerland. The picture […]
Pharmaceutical Companies to Raise Prices on Over 500 Drugs in the US in January
/cloudfront-us-east-2.images.arcpublishing.com/reuters/Y7UGTRYPVJKJ5I6F472NPLEYCI.jpg?fit=1024%2C1024&ssl=1)
Pharmaceutical companies including Pfizer of the US, Sanofi of France, and Takeda Pharmaceutical are expected to raise the prices of more than 500 drugs in the United States in January next year. Photograph taken in August 2019 (2023 Reuters / Yves Herman / Illustration / File Photo) NEW YORK (Reuters) – Pharmaceutical companies including Pfizer […]
